Q-omics provides the consensus-scored C7orf57 profile across patient tissues and cancer cell-line models. C7orf57 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, C7orf57 is differentially expressed in 9, with the highest sampling consensus in KIRP. Additionally, C7orf57 RNA expression shows 17,088 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight THCA, KIRP, and UVM as cancer lineages where C7orf57 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C7orf57 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C7orf57 survival associations across molecular data types. C7orf57 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C7orf57 RNA expression–survival associations across cancer types. High C7orf57 expression shows unfavorable associations in THCA, LGG, STAD, UVM and GBM, but favorable associations in SKCM. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify THCA as the clearest survival context for C7orf57 RNA expression.
This table summarizes C7orf57 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRP for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for C7orf57. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C7orf57 shows lower tumor expression in LUSC and LUAD and higher tumor expression in KIRP, KICH, BRCA and BLCA. The KIRP box plot shows higher C7orf57 RNA expression in tumor versus normal tissue (log2 FC = +0.735, t-test p < 0.001).
This table shows molecular features associated with C7orf57 in patient tissues and cancer cell lines. In patient samples, C7orf57 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, C7orf57 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BREAST and SKIN.
